Top Markets
Coin of the day
Mallinckrodt plc Mallinckrodt plc

Mallinckrodt plc

MNK
Xếp hạng trong cổ phiếu #30228
Mallinckrodt plc operates as a global pharmaceutical company, engaged in the... Mallinckrodt plc operates as a global pharmaceutical company, engaged in the development, manufacturing, marketing, and distribution of specialized medical products and therapies. Its extensive reach covers the United States, Europe, the Middle East, Africa, and various other international markets. The firm's business operations are segmented into two core divisions: Specialty Brands and Specialty Generics. Under its Specialty Brands arm, Mallinckrodt offers a range of pharmaceuticals for autoimmune and rare diseases, spanning therapeutic areas such as neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology. The branded portfolio also encompasses immunotherapy solutions, critical care treatments for neonatal respiratory conditions, pain management drugs, cultured skin substitutes, and gastrointestinal remedies. Key branded products include Acthar Gel, a corticotropin injection prescribed for conditions like rheumatoid arthritis, infantile spasms, and multiple sclerosis; INOmax, a vasodilator used to enhance oxygenation and lessen the need for extracorporeal membrane oxygenation; the Therakos photopheresis platform for immunotherapy; Amitiza, a treatment for constipation; and StrataGraft, designed for adults with deep partial-thickness burns. In its development pipeline, Mallinckrodt is advancing Terlipressin for hepatorenal syndrome and SLN 501, a ribonucleic acid silencing therapeutic. Additionally, through its Specialty Generics segment, the company supplies specialized generic medications and active pharmaceutical ingredients (APIs). Mallinckrodt's branded offerings are marketed to a diverse array of healthcare professionals and institutions, including physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. The company has also forged a strategic collaboration with Silence Therapeutics plc to develop and commercialize ribonucleic acid interference (RNAi) drug targets. Established in 1867, Mallinckrodt plc maintains its headquarters in Dublin, Ireland.
Giá cổ phiếu
$0.1
Đồng bộ lần cuối: 2023-09-19
Vốn hóa thị trường
$17.68M
Thay đổi (1 ngày)
-4.76%
Thay đổi (1 năm)
0.00%
Quốc gia
IE
Giao dịch Mallinckrodt plc (MNK)

Danh mục

Lịch sử chia tách cổ phiếu của Mallinckrodt plc (MNK)
Cổ phiếu Mallinckrodt plc (mã: MNK) đã trải qua tổng cộng 0 lần chia tách.
Lần chia tách gần nhất diễn ra vào ngày Aug 19, 2026.
Một cổ phiếu MNK mua trước ngày Aug 19, 2026 hiện tương đương với 0 cổ phiếu MNK.
Danh sách chia tách cổ phiếu
Năm Chia tách Tỷ lệ Tỷ lệ cộng dồn
Không đủ dữ liệu cho ngày được cung cấp.
Chia tách cổ phiếu của các công ty tương tự hoặc đối thủ
Công ty Số lần chia tách cổ phiếu Tỷ lệ cộng dồn Quốc gia
0 -
DE
0 -
DE
0 -
JP
0 -
CH
5 x119
IN